Tailored Model of Care for Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease

Abstract

Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as nonalcoholic fatty liver disease (NAFLD), is increasing globally, creating a growing public health concern. However, this disease is often not diagnosed, and accurate data on its epidemiology are limited in many geographical regions, making it challenging to provide proper care and implement effective national plans. To combat the increasing disease burden, screening and diagnosis must reach a significant number of high-risk subjects. Addressing MASLD as a healthcare challenge requires a multidisciplinary approach involving prevention, diagnosis, treatment, and care, with collaboration between multiple stakeholders in the healthcare system. This approach must be guided by national and global strategies, to be combined with efficient models of care developed through a bottom-up process. This review article highlights the pillars of the MASLD model of care, including screening, risk stratification, and establishing a clinical care pathway for management, in addition to discussing the impact of nomenclature change on the proposed model of care.

Editorial: Emerging therapeutic approaches for non-alcoholic fatty liver disease

“…Additionally, repurposing current and approved medications is an attractive alternative due to the urgent need to develop new therapeutic strategies and the availability of cumulative safety and tolerability data. Recognizing MASLD as a multisystem disease is crucial, necessitating coordinated and interdisciplinary action plans ( 8 ). This Research Topic has collected several ground-breaking articles exploring various emerging therapeutic approaches to the disease.…”